American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer
Open accessThe DOI matches its Crossref record; 295 of the 295 references it cites were found in a registry or an index.
Abstract
Background: Venous thromboembolism (VTE) is a common complication among patients with cancer. Patients with cancer and VTE are at a markedly increased risk for morbidity and mortality. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the prevention and treatment of VTE in patients with cancer. Methods: ASH formed a multidisciplinary guideline panel balanced to minimize potential bias from conflicts of interest. The guideline development process was supported by updated or new systematic evidence reviews. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess evidence and make recommendations. Results: Recommendations address mechanical and pharmacological prophylaxis in hospitalized medical patients with cancer, those undergoing a surgical procedure, and ambulatory patients receiving cancer chemotherapy. The recommendations also address the use of anticoagulation for the initial, short-term, and long-term treatment of VTE in patients with cancer. Conclusions: Strong recommendations include not using thromboprophylaxis in ambulatory patients receiving cancer chemotherapy at low risk of VTE and to use low-molecular-weight heparin (LMWH) for initial treatment of VTE in patients with cancer. Conditional recommendations include using thromboprophylaxis in hospitalized medical patients with cancer, LMWH or fondaparinux for surgical patients with cancer, LMWH or direct oral anticoagulants (DOAC) in ambulatory patients with cancer receiving systemic therapy at high risk of VTE and LMWH or DOAC for initial treatment of VTE, DOAC for the short-term treatment of VTE, and LMWH or DOAC for the long-term treatment of VTE in patients with cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 3×
“The certainty was categorized into 4 levels ranging from very low to high and used a wording template to formulate statements that communicate findings combining size and certainty.(7-9) When conducting a GRADE assessment, investigators consider the width of the confidence intervals (CIs) and power of the analysis (ie…”
MethodSelf-citationThe National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Clinical Practice Guidelines We Can Trust
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Board on Health Care Services, & Institute of Medicine (2011) · National Academies Press eBooks · doi:10.17226/13058 · Cited by 3,081
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Self-citationDevelopment and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Self-citationGRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911 · cited 1×
“The panel selected outcomes of interest for each question a priori, following the approach described in detail elsewhere.(52) In brief, the panel first brainstormed all possible outcomes before rating their relative importance for decision making following the GRADE approach.”
MethodThromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
KHORANA, A. A., FRANCIS, C. W., CULAKOVA, E., KUDERER, N. M., & LYMAN, G. H. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02374.x · Cited by 1,670
Self-citationEdoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Self-citationPrognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Samama, M. M., Cohen, A. T., Darmon, J.-Y., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Nguyen, H., Olsson, C.-G., Turpie, A. G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411103 · Cited by 1,584
Key, N. S., Khorana, A. A., Kuderer, N. M., Bohlke, K., Lee, A. Y. Y., Arcelus, J. I., Wong, S. L., Balaban, E. P., Flowers, C. R., Francis, C. W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01461 · Cited by 1,504
Self-citationOrtel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Self-citationLyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Self-citationApixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., Hale, D., Dunn, J. A., Lyman, G. H., Hutchinson, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8034 · Cited by 1,348
Self-citationAlonso-Coello, P., Schünemann, H. J., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Rada, G., Rosenbaum, S., et al. (2016) · BMJ · doi:10.1136/bmj.i2016 · Cited by 1,317
Self-citationAtkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., Liberati, A., O'Connell, D., Oxman, A. D., Phillips, B., et al. (2004) · BMC Health Services Research · doi:10.1186/1472-6963-4-38 · Cited by 1,235
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Koopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Kearon, C., Gent, M., Hirsh, J., Weitz, J., Kovacs, M. J., Anderson, D. R., Turpie, A. G., Green, D., Ginsberg, J. S., Wells, P., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903253401201 · Cited by 1,072
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer
Agnelli, G., Becattini, C., Meyer, G., Muñoz, A., Huisman, M. V., Connors, J. M., Cohen, A., Bauersachs, R., Brenner, B., Torbicki, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915103 · Cited by 1,067
Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer
Bergqvist, D., Agnelli, G., Cohen, A. T., Eldor, A., Nilsson, P. E., Le Moigne-Amrani, A., & Dietrich-Neto, F. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012385 · Cited by 1,052
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Leizorovicz, A., Cohen, A. T., Turpie, A. G. G., Olsson, C.-G., Vaitkus, P. T., & Goldhaber, S. Z. (2004) · Circulation · doi:10.1161/01.cir.0000138928.83266.24 · Cited by 955
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919
Guidelines International Network: Toward International Standards for Clinical Practice Guidelines
Qaseem, A., Forland, F., Macbeth, F., Ollenschläger, G., Phillips, S., van der Wees, P., & for the Board of Trustees of the Guidelines International Network* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-7-201204030-00009 · Cited by 902
Self-citation(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Cohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Apixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Self-citationSchünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
Self-citationAlonso-Coello, P., Oxman, A. D., Moberg, J., Brignardello-Petersen, R., Akl, E. A., Davoli, M., Treweek, S., Mustafa, R. A., Vandvik, P. O., Meerpohl, J., et al. (2016) · BMJ · doi:10.1136/bmj.i2089 · Cited by 814
Self-citationLong-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Conflict of Interest in Medical Research, Education, and Practice
(2009) · National Academies Press eBooks · doi:10.17226/12598 · Cited by 807
Meyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1729 · Cited by 796
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.-P., Azarian, R., Laurent, M., Hirsch, J.-L., Ferrari, E., Bosson, J.-L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371002 · Cited by 782
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007) · Cancer · doi:10.1002/cncr.23062 · Cited by 781
Self-citationPrediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
Self-citationCuker, A., Arepally, G. M., Chong, B. H., Cines, D. B., Greinacher, A., Gruel, Y., Linkins, L. A., Rodner, S. B., Selleng, S., Warkentin, T. E., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024489 · Cited by 750
Self-citationRivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
Khorana, A. A., Soff, G. A., Kakkar, A. K., Vadhan-Raj, S., Riess, H., Wun, T., Streiff, M. B., Garcia, D. A., Liebman, H. A., Belani, C. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814630 · Cited by 719
Self-citationLyman, G. H., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., Gates, L. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1118 · Cited by 713
Self-citationHull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Trowbridge, A. A., Elliott, C. G., Lerner, R. G., Hall, J., Sparling, T., Brettell, H. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261502 · Cited by 700
Schünemann, H. J., Wiercioch, W., Etxeandia, I., Falavigna, M., Santesso, N., Mustafa, R., Ventresca, M., Brignardello-Petersen, R., Laisaar, K.-T., Kowalski, S., et al. (2014) · Canadian Medical Association Journal · doi:10.1503/cmaj.131237 · Cited by 686
Self-citationFarge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Self-citationKakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., & Williamson, R. C. N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.002 · Cited by 650
Schünemann, H. J., Wiercioch, W., Brozek, J., Etxeandia-Ikobaltzeta, I., Mustafa, R. A., Manja, V., Brignardello-Petersen, R., Neumann, I., Falavigna, M., Alhazzani, W., et al. (2017) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.09.009 · Cited by 645
Self-citationEyer, M. M., Amama, M. I. S., Lexander, A., Ohen, T. H. C., Ean, J., Armon, V. D., Esjardins, L. O. D., Ldor, A. M. E., Anbon, C. H. J., Eizorovicz, A. L. L., et al. (1999) · Cited by 623
d -Dimer Testing to Determine the Duration of Anticoagulation Therapy
Palareti, G., Cosmi, B., Legnani, C., Tosetto, A., Brusi, C., Iorio, A., Pengo, V., Ghirarduzzi, A., Pattacini, C., Testa, S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054444 · Cited by 622
Aspirin for Preventing the Recurrence of Venous Thromboembolism
Becattini, C., Agnelli, G., Schenone, A., Eichinger, S., Bucherini, E., Silingardi, M., Bianchi, M., Moia, M., Ageno, W., Vandelli, M. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114238 · Cited by 620
Büller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E. M., Cariou, R., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00007 · Cited by 617
Lee, A. Y. Y., Kamphuisen, P. W., Meyer, G., Bauersachs, R., Janas, M. S., Jarner, M. F., Khorana, A. A., & for the CATCH Investigators (2015) · JAMA · doi:10.1001/jama.2015.9243 · Cited by 614
Self-citationHull, R. D., Pineo, G. F., Brant, R. F., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.-C., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.022 · Cited by 607
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy
Klerk, C. P. W., Smorenburg, S. M., Otten, H.-M., Lensing, A. W. A., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M. E. M., Richel, D. J., van Tienhoven, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.134 · Cited by 596
Three Months versus One Year of Oral Anticoagulant Therapy for Idiopathic Deep Venous Thrombosis
Agnelli, G., Prandoni, P., Santamaria, M. G., Bagatella, P., Iorio, A., Bazzan, M., Moia, M., Guazzaloca, G., Bertoldi, A., Tomasi, C., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450302 · Cited by 591
Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial
McBane, R. D., Wysokinski, W. E., Le‐Rademacher, J. G., Zemla, T., Ashrani, A., Tafur, A., Perepu, U., Anderson, D., Gundabolu, K., Kuzma, C., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14662 · Cited by 591
Kearon, C., Ageno, W., Cannegieter, S. C., Cosmi, B., Geersing, G. ‐., & Kyrle, P. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13336 · Cited by 587 · cited 1×
“treatment has not been curative (eg, recurrent or progressive disease), and those in whom anticancer treatment is ongoing.(395) In the absence of a contraindication to anticoagulation because of”
BackgroundPrandoni, P., Carta, M., Cogo, A., Ruol, A., Vigo, M., Casara, D., Lensing, A. W. A., Büller, H. R., & ten Cate, J. W. (1992) · The Lancet · doi:10.1016/0140-6736(92)91054-c · Cited by 583
Risk factors for chemotherapy‐associated venous thromboembolism in a prospective observational study
Khorana, A. A., Francis, C. W., Culakova, E., & Lyman, G. H. (2005) · Cancer · doi:10.1002/cncr.21496 · Cited by 565
Self-citationFrequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
Gomez, M. L., Gomez‐Raposo, C., & Lobo Samper, F. (2008) · Cancer · doi:10.1002/cncr.23524 · Cited by 549
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
Goldhaber, S. Z., Leizorovicz, A., Kakkar, A. K., Haas, S. K., Merli, G., Knabb, R. M., & Weitz, J. I. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1110899 · Cited by 547
Dentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Agnelli, G., George, D. J., Kakkar, A. K., Fisher, W., Lassen, M. R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F., & Turpie, A. G. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108898 · Cited by 531
Agnelli, G., Piovella, F., Buoncristiani, P., Severi, P., Pini, M., D'Angelo, A., Beltrametti, C., Damiani, M., Andrioli, G. C., Pugliese, R., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390204 · Cited by 523
Witt, D. M., Nieuwlaat, R., Clark, N. P., Ansell, J., Holbrook, A., Skov, J., Shehab, N., Mock, J., Myers, T., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024893 · Cited by 511
Levine, M., Hirsh, J., Arnold, A., Gent, M., Levine, M., Arnold, A., Bramwell, V., Pritchard, K. I., Stewart, D., Warr, D., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90008-6 · Cited by 510
Thromboembolism in Hospitalized Neutropenic Cancer Patients
Khorana, A. A., Francis, C. W., Culakova, E., Fisher, R. I., Kuderer, N. M., & Lyman, G. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8877 · Cited by 475
Self-citationLow-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
Kay, R., Wong, K. S., Yu, Y. L., Chan, Y. W., Tsoi, T. H., Ahuja, A. T., chan, F. L., Fong, K. Y., Law, C. B., Wong, A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332402 · Cited by 474
Carrier, M., Le Gal, G., Wells, P. S., & Rodger, M. A. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-00008 · Cited by 473 · cited 1×
“Thus, to determine the potential benefits and harms of anticoagulation therapy in this patient population, the panel took into consideration 1 study that evaluated the safety of LMWH in cancer patients with VTEs(298) and a systematic review of patients with symptomatic VTEs who received anticoagulation therapy for $3…”
Self-citationDolovich, L. R., Ginsberg, J. S., Douketis, J. D., Holbrook, A. M., & Cheah, G. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.2.181 · Cited by 468
Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M., & Soyuer, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00871.x · Cited by 455
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
Schulman, S., Wåhlander, K., Lundström, T., Clason, S. B., & Eriksson, H. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030104 · Cited by 454
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients
Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., & Gibson, C. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601747 · Cited by 441
van Dongen, C. J., van den Belt, A. G., Prins, M. H., & Lensing, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub2 · Cited by 433
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Self-citationExtended Oral Anticoagulant Therapy after a First Episode of Pulmonary Embolism
Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M. R., Miccio, M., Imberti, D., Poggio, R., Ageno, W., Pogliani, E., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-1-200307010-00008 · Cited by 400
Deitcher, S. R., Kessler, C. M., Merli, G., Rigas, J. R., Lyons, R. M., & Fareed, J. (2006) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029606293692 · Cited by 392
Hull, R. D., Schellong, S. M., Tapson, V. F., Monreal, M., Samama, M.-M., Nicol, P., Vicaut, E., Turpie, A. G. G., Yusen, R. D., & study*, F. T. E. (. P. F. V. T. I. A. I. M. P. W. P. I. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-1-201007060-00004 · Cited by 384
RASMUSSEN, M. S., JORGENSEN, L. N., WILLE‐JØRGENSEN, P., NIELSEN, J. D., HORN, A., MOHN, A. C., SØMOD, L., & OLSEN, B. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02153.x · Cited by 371
Monreal, M., Alastrue, A., Rull, M., Mira, X., Muxart, J., Rosell, R., & Abad, A. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650254 · Cited by 370
Merli, G., Spiro, T. E., Olsson, C.-G., Abildgaard, U., Davidson, B. L., Eldor, A., Elias, D., Grigg, A., Musset, D., Rodgers, G. M., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-3-200102060-00009 · Cited by 362
Schünemann, H. J., Mustafa, R., Brozek, J., Santesso, N., Alonso-Coello, P., Guyatt, G., Scholten, R., Langendam, M., Leeflang, M. M., Akl, E. A., et al. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.01.032 · Cited by 350
Self-citationAnticoagulants for acute ischaemic stroke
Sandercock, P. A., Counsell, C., & Kamal, A. K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000024.pub3 · Cited by 346
Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Forcier, A. J., Edwards, R. L., Headley, E., Kim, S.-H., O'Donnell, J. F., et al. (1984) · Cancer · doi:10.1002/1097-0142(19840515)53:10<2046::aid-cncr2820531007>3.0.co;2-f · Cited by 343
Schünemann, H. J., Al-Ansary, L. A., Forland, F., Kersten, S., Komulainen, J., Kopp, I. B., Macbeth, F., Phillips, S. M., Robbins, C., van der Wees, P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-1885 · Cited by 337 · cited 8×
“Conflicts of interest of all participants were managed according to ASH policies based on recommendations of the National Academy of Medicine(47) and GIN.(4) At the time of appointment, a majority of the guideline panel, including 1 of the clinical cochairs and the vice chair, had no conflicts of interest as defined a…”
BackgroundMethodInfluentialSelf-citationAgnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
The Vexing Problem of Guidelines and Conflict of Interest: A Potential Solution
Guyatt, G., Akl, E. A., Hirsh, J., Kearon, C., Crowther, M., Gutterman, D., Lewis, S. Z., Nathanson, I., Jaeschke, R., & Schünemann, H. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-11-201006010-00254 · Cited by 325
Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6844 · Cited by 323
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
Prolonged thromboprophylaxis with Low Molecular Weight heparin for abdominal or pelvic surgery
Rasmussen, M. S., Jørgensen, L. N., & Wille-Jørgensen, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004318.pub2 · Cited by 316
Verso, M., Agnelli, G., Bertoglio, S., Di Somma, F. C., Paoletti, F., Ageno, W., Bazzan, M., Parise, P., Quintavalla, R., Naglieri, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.084 · Cited by 303
Erkens, P. M., & Prins, M. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub3 · Cited by 301
(1997) · British Journal of Surgery · doi:10.1046/j.1365-2168.1997.d01-3882.x · Cited by 296
Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations.
Schünemann, H. J., Best, D., Vist, G. E., & Oxman, A. D. (2003) · PubMed Central · Cited by 289
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Li, A., Garcia, D. A., Lyman, G. H., & Carrier, M. (2019) · Thrombosis Research · doi:10.1016/j.thromres.2018.02.144 · Cited by 288
Self-citationPrins, M. H., Lensing, A. W. A., Brighton, T. A., Lyons, R. M., Rehm, J., Trajanovic, M., Davidson, B. L., Beyer-Westendorf, J., Pap, Á. F., Berkowitz, S. D., et al. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70018-3 · Cited by 283
High risk of the critically ill for venous thromboembolism
CADE, J. F. (1982) · Critical Care Medicine · doi:10.1097/00003246-198207000-00006 · Cited by 280
Subcutaneous heparin treatment increases survival in small cell lung cancer
Lebeau, B., Chastang, C., Brechot, J.-M., Capron, F., Dautzenberg, B., Delaisements, C., Mornet, M., Brun, J., Hurdebourcq, J.-P., & Lemarie, E. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e · Cited by 277
Use of Low Molecular Weight Heparin in Preventing Thromboembolism in Trauma Patients
Knudson, M. M., Morabito, D., Paiement, G. D., & Shackleford, S. (1996) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/00005373-199609000-00010 · Cited by 273
Direct Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
Pelzer, U., Opitz, B., Deutschinoff, G., Stauch, M., Reitzig, P. C., Hahnfeld, S., Müller, L., Grunewald, M., Stieler, J. M., Sinn, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1481 · Cited by 268
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Di Nisio, M., Porreca, E., Ferrante, N., Otten, H.-M., Cuccurullo, F., & Rutjes, A. W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008500.pub2 · Cited by 264
Self-citationAspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation · doi:10.1161/circulationaha.114.008828 · Cited by 262
Cancer and Venous Thromboembolic Disease: A Review
Donnellan, E., & Khorana, A. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0214 · Cited by 252
Self-citationCouturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
PERRY, J. R., JULIAN, J. A., LAPERRIERE, N. J., GEERTS, W., AGNELLI, G., ROGERS, L. R., MALKIN, M. G., SAWAYA, R., BAKER, R., FALANGA, A., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03973.x · Cited by 249
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness
Spyropoulos, A. C., Ageno, W., Albers, G. W., Elliott, C. G., Halperin, J. L., Hiatt, W. R., Maynard, G. A., Steg, P. G., Weitz, J. I., Suh, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805090 · Cited by 248
Thromboprophylaxis for trauma patients
Barrera-Lozano, L. M., Perel, P., Ker, K., Cirocchi, R., Farinella, E., & Uribe, C. H. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008303.pub2 · Cited by 247
Alikhan, R., Cohen, A. T., Combe, S., Samama, M. M., Desjardins, L., Eldor, A., Janbon, C., Leizorovicz, A., Olsson, C.-G., & Turpie, A. G. (2003) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200306000-00004 · Cited by 244
Nurmohamed, M. T., van Riel, A. M., Henkens, C. M. A., Koopman, M. M. W., Que, G. T. H., D’Azemar, P., Büller, H. R., ten Cate, J. W., Hoek, J. A., van der Meer, J., et al. (1996) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1650250 · Cited by 242
Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry
Ageno, W., Riva, N., Schulman, S., Beyer-Westendorf, J., Bang, S. M., Senzolo, M., Grandone, E., Pasca, S., Di Minno, M. N. D., Duce, R., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.3184 · Cited by 233
Self-citationSimonneau, G. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.1993.00410130045005 · Cited by 232
CARRIER, M., LE GAL, G., CHO, R., TIERNEY, S., RODGER, M., & LEE, A. Y. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03326.x · Cited by 229
Self-citationHo, K. M., & Tan, J. A. (2013) · Circulation · doi:10.1161/circulationaha.113.002690 · Cited by 222
Karthaus, M., Kretzschmar, A., Kröning, H., Biakhov, M., Irwin, D., Marschner, N., Slabber, C., Fountzilas, G., Garin, A., Abecasis, N. G. F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj059 · Cited by 221
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015
Streiff, M. B., Holmstrom, B., Ashrani, A., Bockenstedt, P. L., Chesney, C., Eby, C., Fanikos, J., Fenninger, R. B., Fogerty, A. E., Gao, S., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0133 · Cited by 218
Self-citationHeparin Prophylaxis Study Group, & Gårdlund, B. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91009-0 · Cited by 217
Impact of Venous Thromboembolism and Anticoagulation on Cancer and Cancer Survival
Kuderer, N. M., Ortel, T. L., & Francis, C. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4584 · Cited by 216
Adjunctive intermittent pneumatic compression for venous thromboprophylaxis.
Arabi, Y. M., Al-Hameed, F., Burns, K. E. A., Mehta, S., Alsolamy, S. J., Alshahrani, M. S., Mandourah, Y., Almekhlafi, G. A., Almaani, M., Al Bshabshe, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816150 · Cited by 215
Posch, F., Königsbrügge, O., Zielinski, C., Pabinger, I., & Ay, C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.011 · Cited by 215
Self-citationKuderer, N. M., Khorana, A. A., Lyman, G. H., & Francis, C. W. (2007) · Cancer · doi:10.1002/cncr.22892 · Cited by 212
Self-citationLindmarker, P., Holmström, M., Granqvist, S., Johnsson, H., & Lockner, D. (1994) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648836 · Cited by 210
Chee, C. E., Ashrani, A. A., Marks, R. S., Petterson, T. M., Bailey, K. R., Melton, L. J., & Heit, J. A. (2014) · Blood · doi:10.1182/blood-2014-01-549733 · Cited by 210
KOVACS, M. J., KAHN, S. R., RODGER, M., ANDERSON, D. R., ANDREOU, R., MANGEL, J. E., MORROW, B., CLEMENT, A. M., & WELLS, P. S. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02613.x · Cited by 200
Dahan, R., Houlbert, D., Caulin, C., Cuzin, E., Viltart, C., Woler, M., & Segrestaa, J. M. (1986) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000215286 · Cited by 199
LOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKE
Mccarthy, S. T., Robertson, D., Turner, J. J., Hawkey, C. J., & Macey, D. J. (1977) · The Lancet · doi:10.1016/s0140-6736(77)90728-0 · Cited by 199
Agnelli, G., Buller, H. R., Cohen, A., Gallus, A. S., Lee, T. C., Pak, R., Raskob, G. E., Weitz, J. I., & Yamabe, T. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13153 · Cited by 197
Three months vs. one year of oral anticoagulant therapy for idiopathic deep venous thrombosis
Agnelli, G., Prandoni, P., & Santamaria, M. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00547-5 · Cited by 196
Breddin, H. K., Hach-Wunderle, V., Nakov, R., & Kakkar, V. V. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440902 · Cited by 195
WESTRICH, G. H., & SCULCO, T. P. (1996) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-199606000-00004 · Cited by 195
Venous Thromboembolism Risk in Patients With Cancer Receiving Chemotherapy: A Real-World Analysis
Lyman, G. H., Eckert, L., Wang, Y., Wang, H., & Cohen, A. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0226 · Cited by 194
Self-citationCastellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Self-citationChahinian, A. P., Propert, K. J., Ware, J. H., Zimmer, B., Perry, M. C., Hirsh, V, Skarin, A., Kopel, S., Holland, J. F., & Comis, R. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.993 · Cited by 193
Low Rate of Venous Thromboembolism After Craniotomy for Brain Tumor Using Multimodality Prophylaxis
Goldhaber, S. Z., Dunn, K., Gerhard-Herman, M., Park, J. K., & Black, P. M. (2002) · Chest · doi:10.1378/chest.122.6.1933 · Cited by 193
Lyman, G. H. (2011) · Cancer · doi:10.1002/cncr.25714 · Cited by 190
Self-citationLEVINE, M. N., GU, C., LIEBMAN, H. A., ESCALANTE, C. P., SOLYMOSS, S., DEITCHMAN, D., RAMIREZ, L., & JULIAN, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04693.x · Cited by 190
Alikhan, R., Forster, R., & Cohen, A. T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003747.pub4 · Cited by 182
Wein, L. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.14.1476 · Cited by 182
Haas, S. K., Freund, M., Heigener, D., Heilmann, L., Kemkes-Matthes, B., Tempelhoff, G.-F. V., Melzer, N., & Kakkar, A. K. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611433769 · Cited by 180
Macbeth, F., Noble, S., Evans, J., Ahmed, S., Cohen, D., Hood, K., Knoyle, D., Linnane, S., Longo, M., Moore, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0268 · Cited by 178
Self-citationCrawford, J., Allen, J., Armitage, J., Blayney, D. W., Cataland, S. R., Heaney, M. L., Htoy, S., Hudock, S., Kloth, D. D., Kuter, D. J., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0075 · Cited by 177
Self-citationLow-Molecular-Weight Heparin and Mortality in Acutely Ill Medical Patients
Kakkar, A. K., Cimminiello, C., Goldhaber, S. Z., Parakh, R., Wang, C., & Bergmann, J.-F. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111288 · Cited by 175
Wells, P. S., Anderson, D. R., Rodger, M. A., Forgie, M. A., Florack, P., Touchie, D., Morrow, B., Gray, L., O’Rourke, K., Wells, G., et al. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.7.733 · Cited by 174
Carrier, M., Cameron, C., Delluc, A., Castellucci, L., Khorana, A. A., & Lee, A. Y. Y. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.09.039 · Cited by 172
Self-citationAnticoagulation for the long-term treatment of venous thromboembolism in people with cancer
Kahale, L. A., Hakoum, M. B., Tsolakian, I. G., Alturki, F., Matar, C. F., Terrenato, I., Sperati, F., Barba, M., Yosuico, V. E. D., Schünemann, H. J., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub5 · Cited by 170
Self-citationLederle, F. A., Zylla, D., MacDonald, R., & Wilt, T. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-9-201111010-00008 · Cited by 167
Raskob, G. E., van Es, N., Segers, A. E. M., Angchaisuksiri, P., Oh, D., Boda, Z., Lyons, R. M., Meijer, K., Gudz, I., Weitz, J. I., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30057-6 · Cited by 167
Kakkos, S. K., Caprini, J. A., Geroulakos, G., Nicolaides, A. N., Stansby, G., Reddy, D. J., & Ntouvas, I. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005258.pub3 · Cited by 165
van der Hulle, T., den Exter, P. L., Kooiman, J., van der Hoeven, J. J. M., Huisman, M. V., & Klok, F. A. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12605 · Cited by 164
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
Sideras, K., Schaefer, P. L., Okuno, S. H., Sloan, J. A., Kutteh, L., Fitch, T. R., Dakhil, S. R., Levitt, R., Alberts, S. R., Morton, R. F., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.6.758 · Cited by 163
Graduated compression stockings for prevention of deep vein thrombosis
Sachdeva, A., Dalton, M., Amaragiri, S. V., & Lees, T. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001484.pub3 · Cited by 159
Diagnosis and management of subsegmental pulmonary embolism
LE GAL, G., RIGHINI, M., PARENT, F., VAN STRIJEN, M., & COUTURAUD, F. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01819.x · Cited by 158
Young, A., Billingham, L. J., Begum, G., Kerr, D. J., Hughes, A. I., Rea, D. W., Shepherd, S. F., Stanley, A., Sweeney, A., Wilde, J. T., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60205-1 · Cited by 158
Thromboembolic and Bleeding Complications Following St. Jude Medical Valve Replacement
Hering, D., Piper, C., Bergemann, R., Hillenbach, C., Dahm, M., Huth, C., & Horstkotte, D. (2005) · CHEST Journal · doi:10.1378/chest.127.1.53 · Cited by 153
Lack of Evidence to Support Thromboprophylaxis in Hospitalized Medical Patients with Cancer
Carrier, M., Khorana, A. A., Moretto, P., Gal, G. L., Leaf, R. K., & Zwicker, J. I. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.09.015 · Cited by 149
Self-citationPrimary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Nisio, M. D., Porreca, E., Candeloro, M., Tursi, M. D., Russi, I., & Rutjes, A. W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008500.pub4 · Cited by 149
Junqueira, D. R., Zorzela, L. M., & Perini, E. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007557.pub3 · Cited by 147
Ninet, J., Bachet, P., Prandoni, P., Ruol, A., Vigo, M., Barret, A., Mericq, O., Boneu, B., Janvier, G., Duroux, P., et al. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647660 · Cited by 147
Lopaciuk, S., Meissner, A. J., Filipecki, S., Zawilska, K., Sowier, J., Ciesielski, L., Bielawiec, M., Glowinski, S., & Czestochowska, E. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1656309 · Cited by 146
Agnelli, G., Becattini, C., Bauersachs, R., Brenner, B., Campanini, M., Cohen, A., Connors, J., Fontanella, A., Gussoni, G., Huisman, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668523 · Cited by 146
Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study
Jara‐Palomares, L., Solier-López, A., Elías-Hernández, T., Asensio-Cruz, M., Blasco-Esquivias, I., Marín-Barrera, L., de la Borbolla-Artacho, M. R., Praena‐Fernández, J. M., Romero, E. M., Navarro‐Herrero, S., et al. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.004 · Cited by 144
Zwicker, J. I., Liebman, H. A., Bauer, K. A., Caughey, T., Campigotto, F., Rosovsky, R. P. G., Mantha, S. H., Kessler, C. M., Eneman, J. D., Raghavan, V. R., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12163 · Cited by 142
Ramos, R., Salem, B. I., Pawlikowski, M. P. D., Coordes, C., Eisenberg, S. B., & Leidenfrost, R. (1996) · CHEST Journal · doi:10.1378/chest.109.1.82 · Cited by 140
Physical methods for preventing deep vein thrombosis in stroke
Naccarato, M., Grandi, F. C., Dennis, M. S., & Sandercock, P. A. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001922.pub3 · Cited by 139
Kakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 138
Sandercock, P. A., & Leong, T. S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000119.pub4 · Cited by 135
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Middeldorp, S., Prins, M. H., & Hutten, B. A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001367.pub3 · Cited by 133
Anticoagulants for acute ischaemic stroke
Sandercock, P. A., Counsell, C. E., & Kane, E. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000024.pub4 · Cited by 130
(2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1077 · Cited by 129
Thrombosis Prophylaxis in Patient Populations With a Central Venous Catheter: A Systematic Review
Klerk, C. P. W., Smorenburg, S. M., & Buller, H. R. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.16.1913 · Cited by 128
Lloyd, N. S., Douketis, J. D., Moinuddin, I. A., Lim, W., & Crowther, M. A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02847.x · Cited by 126
van der Hulle, T., den Exter, P. L., Planquette, B., Meyer, G., Soler, S., Monréal, M., Jiménez, D., Portillo, A. K., O'Connell, C. L., Liebman, H. A., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13172 · Cited by 124
Maurer, L. H., Herndon, J. E., Hollis, D. R., Aisner, J., Carey, R. W., Skarin, A. T., Perry, M. C., Eaton, W. L., Zacharski, L., Hammond, S., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3378 · Cited by 123
Long-term psychological consequences of symptomatic pulmonary embolism: a qualitative study
Noble, S., Lewis, R. P., Whithers, J., Lewis, S., & Bennett, P. D. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004561 · Cited by 123
Self-citationGinzburg, E., Cohn, S. M., Lopez, J., Jackowski, J., Brown, M., & Hameed, S. M. (2003) · British journal of surgery · doi:10.1002/bjs.4309 · Cited by 122
Kraaijpoel, N., Bleker, S. M., Meyer, G., Mahé, I., Martín, A. J. M., Bertoletti, L., Rutten, A., Beyer‐Westendorf, J., Porreca, E., Boulon, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01977 · Cited by 120
Akl, E. A., Gunukula, S., Barba, M., Yosuico, V. E. D., van Doormaal, F. F., Kuipers, S., Middeldorp, S., Dickinson, H. O., Bryant, A., & Schünemann, H. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006652.pub3 · Cited by 118
Schünemann, H. J., Osborne, M., Moss, J., Manthous, C., Wagner, G., Sicilian, L., Ohar, J., McDermott, S., Lucas, L., & Jaeschke, R. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0126st · Cited by 115
Schulman, S., Zondag, M., Linkins, L., Pasca, S., Cheung, Y. W., de Sancho, M., Gallus, A. S., Lecumberri, R., Molnar, S., Ageno, W., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12955 · Cited by 113
Self-citationPrins, M. H., Gelsema, R. G., Sing, A. K., van Heerde, L. R., & den Ottolander, G. J. H. (2009) · Haemostasis · doi:10.1159/000215979 · Cited by 111
Venous thromboembolism prevention in gynecologic cancer surgery: A systematic review
Einstein, M. H., Pritts, E. A., & Hartenbach, E. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.03.004 · Cited by 109
Noble, S., Shelley, M. D., Coles, B., Williams, S. M., Wilcock, A., & Johnson, M. J. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70149-9 · Cited by 109
Self-citationPaciaroni, M., Agnelli, G., Venti, M. P., Alberti, A., Acciarresi, M., & Caso, V. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04241.x · Cited by 107
Patients’ Experiences of LIving with CANcer-associated thrombosis: the PELICAN study
Noble, S., Prout, H., & Nelson, A. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s79373 · Cited by 106
Self-citationNoble, S., Matzdorff, A. C., Maraveyas, A., Holm, M., & Pisa, G. (2015) · Haematologica · doi:10.3324/haematol.2015.127126 · Cited by 106
Self-citationDavies, G. A., Lazo‐Langner, A., Gándara, E., Rodger, M. A., Tagalakis, V., Louzada, M., Corpuz, R., & Kovacs, M. J. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.04.003 · Cited by 106
Sandset, P. M., Dahl, T., Stiris, M., Rostad, B., Scheel, B., & Abildgaard, U. (1990) · PubMed · Cited by 105
Romera, A., Cairols, M. A., Vila-Coll, R., Martí-Mestre, X., Colomé, E., Bonell-Pascual, A., & Lapiedra, O. (2009) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2008.11.030 · Cited by 105
Blood Coagulation and Thrombosis in Patients with Ovarian Malignancy
Tempelhoff, G.-F. V., Dietrich, M., Niemann, F., Schneider, D. M., Hommel, G., & Heilmann, L. (1997) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1655988 · Cited by 103
ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism
Zer, A., Moskovitz, M. T., Hwang, D. M., Klement, A. H., Fridel, L., Korpanty, G. J., Dudnik, E., Peled, N., Shochat, T., Leighl, N. B., et al. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.007 · Cited by 103
Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients
Kanaan, A. O., Silva, M. A., Donovan, J. L., Roy, T., & Al‐Homsi, A. S. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.015 · Cited by 102
Parenteral anticoagulation in ambulatory patients with cancer
Akl, E. A., Kahale, L. A., Hakoum, M. B., Matar, C. F., Sperati, F., Barba, M., Yosuico, V. E., Terrenato, I., Synnot, A., & Schünemann, H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006652.pub5 · Cited by 102
Self-citation
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Khan, F., Tritschler, T., Kahn, S. R., & Rodger, M. A. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32658-1 · Cited by 753
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Cancer-associated venous thromboembolism
Khorana, A. A., Mackman, N., Falanga, A., Pabinger, I., Noble, S., Ageno, W., Moik, F., & Lee, A. Y. Y. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00336-y · Cited by 470
Self-citation
Metadata
- Authors
- Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., Noble, S., Sexton, E. A., Stenehjem, D., Wiercioch, W., Kahale, L. A., & Alonso-Coello, P.
- Venue
- Blood Advances
- Publisher
- American Society of Hematology
- Published
- 2021-02-11
- Volume
- 5
- Issue
- 4
- Pages
- 927-974
- ISSN
- 2473-9529 (ISSN-L)
- 2473-9537
- OpenAlex
- W3127460195
- Cited by
- 893
- References
- 295
- FWCI
- 104.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.